Search

Displaying results 5151 - 5160 of 10000 in total
  1. Drug

    Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10776
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10777
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10778
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10802
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen

    go.drugbank.com/drugs/DB11036
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    LAX-101

    go.drugbank.com/drugs/DB05301
    Investigational

    The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.

  7. Drug

    Trevogrumab

    go.drugbank.com/drugs/DB15159
    Investigational

    and Healthy Adult Men). … Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women

  8. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  9. Drug

    Hypothiocyanite ion

    go.drugbank.com/drugs/DB15309
    Investigational

    Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).

  10. Drug

    Trelagliptin

    go.drugbank.com/drugs/DB15323
    Investigational

    Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").